Download PDF
Am J Perinatol 2015; 32(08): 803-808
DOI: 10.1055/s-0034-1396694
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Differing Effects of Resibufagenin on Cinobufatalin- versus Marinobufagenin-Induced Preeclampsia in a Rodent Model

Jules B. Puschett
1   Texas A&M Colleges of Medicine and of Veterinary Medicine and Biomedical Sciences, Texas Veterinary Medical Center, College Station, Texas
2   Scott and White Healthcare, Temple, Texas
,
Biresh Kumar
2   Scott and White Healthcare, Temple, Texas
,
M.M. Kamran Abbas
1   Texas A&M Colleges of Medicine and of Veterinary Medicine and Biomedical Sciences, Texas Veterinary Medical Center, College Station, Texas
› Author Affiliations
Further Information

Publication History

18 June 2014

29 October 2014

Publication Date:
29 December 2014 (online)

    Permissions and Reprints

Abstract

Objective Previous studies from this laboratory have demonstrated that the bufodienolide, marinobufagenin, causes a syndrome in the pregnant rat that resembles human preeclampsia. Furthermore, marinobufagenin urinary excretion is elevated in approximately 85% of preeclamptic patients. Resibufagenin, an antagonist to marinobufagenin, completely prevents the syndrome (hypertension, proteinuria, and intrauterine growth restriction) if given from early pregnancy.

Study Design We investigated the effects of another bufodienolide, cinobufatalin, to determine if it, likewise, could induce the rat “preeclamptic” syndrome, which it did. We then examined whether resibufagenin could prevent the syndrome due to cinobufatalin.

Results Resibufagenin improved hypertension but not proteinuria, and did not prevent uterine growth restriction.

Conclusion We conclude that more than one bufodienolide may induce the preeclamptic syndrome and that each may require a specific antagonist to prevent (or treat) the syndrome.

Keywords

preeclampsia - bufodienolides - marinobufagenin - resibufogenin - cinobufatalin
 

  • References

  • 1 Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002; 269 (10) 2440-2448
    CrossrefPubMedGoogle Scholar
  • 2 Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293 (2) C509-C536
    CrossrefPubMedGoogle Scholar
  • 3 Abel JJ, Macht DJ. Two crystalline pharmacological agents obtained from the tropical toad, Bufo agun. J Pharmacol Exp Ther 1959; 13: 319-377
    PubMedGoogle Scholar
  • 4 Fieser LF, Fieser M. Steroids. 1st ed. New York, NY: Reinhold Publishing Corporation; 1959: 727-809
    Google Scholar
  • 5 Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998; 48 (1) 1-29
    CrossrefPubMedGoogle Scholar
  • 6 Ianosi-Irimie M, Vu HV, Whitbred JM , et al. A rat model of preeclampsia. Clin Exp Hypertens 2005; 27 (8) 605-617
    CrossrefPubMedGoogle Scholar
  • 7 Vu HV, Ianosi-Irimie MR, Pridjian CA , et al. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25 (5) 520-528
    CrossrefPubMedGoogle Scholar
  • 8 Horvat D, Severson J, Uddin MN, Mitchell B, Puschett JB. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy 2010; 29 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 9 Puschett JB. Marinobufagenin predicts and resibufogenin prevents preeclampsia: a review of the evidence. Am J Perinatol 2012; 29 (10) 777-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Abi-Ghanem D, Lai X, Berghman LR , et al. A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids. J Immunoassay Immunochem 2011; 32 (1) 31-46
    CrossrefPubMedGoogle Scholar